AAM
EDIT icon

Azzad Asset Management’s Editas Medicine EDIT Stock Holding History

Azzad Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,655
Closed -$207K – 333
2021
Q2 		$207K Buy
+3,655
New +$135K 0.03% 319

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Azzad Asset Management's EDIT Position: Q3 2021 in Review

Azzad Asset Management sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 3,655 shares — an estimated $207K sold.

Azzad Asset Management first reported a position in EDIT in Q2 2021 and held it in 1 quarter. The position peaked at $207K in Q2 2021. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

  • Azzad Asset Management reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
  • Azzad Asset Management sold 3,655 Editas Medicine shares in Q3 2021, an estimated $207K.
  • Azzad Asset Management first reported a position in Editas Medicine in Q2 2021 and held it in 1 quarter.
  • Azzad Asset Management's Editas Medicine position peaked at $207K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Azzad Asset Management's 13F filing for Q3 2021, filed 1 Apr 2024.